TY - JOUR
T1 - Robust multi-label transfer feature learning for early diagnosis of Alzheimer’s disease
AU - Alzheimer’s Disease Neuroimaging Initiative
AU - Cheng, Bo
AU - Liu, Mingxia
AU - Zhang, Daoqiang
AU - Shen, Dinggang
N1 - Funding Information:
Acknowledgements Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuron Imaging at the University of California, Los Angeles. This work was supported by the National Natural Science Foundation of China (Nos. 61602072, 61573023, 61732006, and 61473149), Chongqing Cutting-edge and Applied Foundation Research Program (Grant No. cstc2016jcyjA0063), Scientific and Technological Research Program of Chongqing Municipal Education Commission (Grant Nos. KJ1401010, KJ1601003, KJ1601015, KJ1710248, KJ1710257), NIH grants (AG041721, AG049371, AG042599, AG053867), Key Laboratory of Chongqing Municipal Institutions of Higher Education (Grant No. [2017]3), and Program of Chongqing Development and Reform Commission (Grant No. 2017[1007]).
Funding Information:
Data collection and sharing for this project was funded by the Alzheimer?s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., as well as non-profit partners the Alzheimer?s Association and Alzheimer?s Drug Discovery Foundation, with participation from the U.S. Food and Drug Administration. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer?s Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuron Imaging at the University of California, Los Angeles. This work was supported by the National Natural Science Foundation of China (Nos. 61602072, 61573023, 61732006, and 61473149), Chongqing Cutting-edge and Applied Foundation Research Program (Grant No. cstc2016jcyjA0063), Scientific and Technological Research Program of Chongqing Municipal Education Commission (Grant Nos. KJ1401010, KJ1601003, KJ1601015, KJ1710248, KJ1710257), NIH grants (AG041721, AG049371, AG042599, AG053867), Key Laboratory of Chongqing Municipal Institutions of Higher Education (Grant No. [2017]3), and Program of Chongqing Development and Reform Commission (Grant No. 2017[1007]).
Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2019/2/15
Y1 - 2019/2/15
N2 - Transfer learning has been successfully used in the early diagnosis of Alzheimer’s disease (AD). In these methods, data from one single or multiple related source domain(s) are employed to aid the learning task in the target domain. However, most of the existing methods utilize data from all source domains, ignoring the fact that unrelated source domains may degrade the learning performance. Also, previous studies assume that class labels for all subjects are reliable, without considering the ambiguity of class labels caused by slight differences between early AD patients and normal control subjects. To address these issues, we propose to transform the original binary class label of a particular subject into a multi-bit label coding vector with the aid of multiple source domains. We further develop a robust multi-label transfer feature learning (rMLTFL) model to simultaneously capture a common set of features from different domains (including the target domain and all source domains) and to identify the unrelated source domains. We evaluate our method on 406 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database with baseline magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. The experimental results show that the proposed rMLTFL method can effectively improve the performance of AD diagnosis, compared with several state-of-the-art methods.
AB - Transfer learning has been successfully used in the early diagnosis of Alzheimer’s disease (AD). In these methods, data from one single or multiple related source domain(s) are employed to aid the learning task in the target domain. However, most of the existing methods utilize data from all source domains, ignoring the fact that unrelated source domains may degrade the learning performance. Also, previous studies assume that class labels for all subjects are reliable, without considering the ambiguity of class labels caused by slight differences between early AD patients and normal control subjects. To address these issues, we propose to transform the original binary class label of a particular subject into a multi-bit label coding vector with the aid of multiple source domains. We further develop a robust multi-label transfer feature learning (rMLTFL) model to simultaneously capture a common set of features from different domains (including the target domain and all source domains) and to identify the unrelated source domains. We evaluate our method on 406 subjects from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database with baseline magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) data. The experimental results show that the proposed rMLTFL method can effectively improve the performance of AD diagnosis, compared with several state-of-the-art methods.
KW - Alzheimer’s disease (AD)
KW - Feature learning
KW - Multi-label learning
KW - Transfer learning
UR - http://www.scopus.com/inward/record.url?scp=85044462330&partnerID=8YFLogxK
U2 - 10.1007/s11682-018-9846-8
DO - 10.1007/s11682-018-9846-8
M3 - Article
C2 - 29589326
AN - SCOPUS:85044462330
VL - 13
SP - 138
EP - 153
JO - Brain Imaging and Behavior
JF - Brain Imaging and Behavior
SN - 1931-7557
IS - 1
ER -